Immunogenic Cell Death in Cancer Therapy
Délégation Paris 5 · Université Paris Cité · +10 more institutions
Abstract
Depending on the initiating stimulus, cancer cell death can be immunogenic or nonimmunogenic. Immunogenic cell death (ICD) involves changes in the composition of the cell surface as well as the release of soluble mediators, occurring in a defined temporal sequence. Such signals operate on a series of receptors expressed by dendritic cells to stimulate the presentation of tumor antigens to T cells. We postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies. Hence, suboptimal regimens (failing to induce ICD), selective alterations in cancer cells (preventing the emission of immunogenic…
Citation impact
- FWCI
- 49.65
- Percentile
- 100%
- References
- 112
Authors
4- GKGuido KroemerCorresponding
Délégation Paris 5, Université Paris Cité, Weatherford College, Sorbonne Paris Cité, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Européen
- LGLorenzo Galluzzi
Délégation Paris 5, Université Paris Cité, Institut Gustave Roussy, Sorbonne Paris Cité
- OKOliver Kepp
Université Paris-Sud, Institut Gustave Roussy, Weatherford College
- LZLaurence Zitvogel
Université Paris-Sud, Inserm, Institut Gustave Roussy
Topics & keywords
- Immunogenic cell death
- Biology
- Immune system
- Immunology
- Programmed cell death
- Cancer
- Effector
- Cancer cell
- Good health and well-being